OverviewSuggest Edit

Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late-stage development for moderate to severe osteoarthritis pain.

Zilretta™ has received Fast Track Designation from the FDA. This designation is given to a drug in clinical development that is intended to treat a serious condition and addresses unmet medical need.

TypePublic
Founded2007
HQBurlington, MA, US
Websiteflexiontherapeutics.com
Employee Ratings3.7
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2018)272(+9%)
Job Openings4
Revenue (FY, 2020)$85.6 M(+18%)
Share Price (Sept 2021)$5.9(-1%)
Cybersecurity ratingAMore

Key People/Management at Flexion Therapeutics

Scott A. Canute

Scott A. Canute

Director
Michael D. Clayman

Michael D. Clayman

Chief Executive Officer & Co-Founder and Director
Melissa Layman

Melissa Layman

Chief Commercial Officer
Frederick Driscoll

Frederick Driscoll

Chief Financial Officer
William T. Andrews

William T. Andrews

Chief Medical Officer
Sandesh Mahatme

Sandesh Mahatme

Director
Show more

Flexion Therapeutics Office Locations

Flexion Therapeutics has an office in Burlington
Burlington, MA, US (HQ)
10 Burlington Mall Road #301
Show all (1)

Flexion Therapeutics Financials and Metrics

Flexion Therapeutics Revenue

Flexion Therapeutics's revenue was reported to be $85.55 m in FY, 2020
USD

Revenue (Q1, 2021)

24.6m

Gross profit (Q1, 2021)

18.5m

Gross profit margin (Q1, 2021), %

75.3%

Net income (Q1, 2021)

(28.6m)

EBIT (Q1, 2021)

(23.1m)

Market capitalization (14-Sept-2021)

296.2m

Closing stock price (14-Sept-2021)

5.9

Cash (31-Mar-2021)

98.7m

EV

262.8m
Flexion Therapeutics's current market capitalization is $296.2 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

355.0k22.5m73.0m85.6m

Cost of goods sold

4.0k7.3m10.0m19.2m

Gross profit

351.0k15.2m63.0m66.3m

Gross profit Margin, %

99%67%86%78%
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

2.2m3.8m7.0m10.6m17.0m21.8m20.1m15.5m23.7m24.6m

Cost of goods sold

2.7m946.0k1.6m1.8m1.4m2.9m2.3m5.5m5.1m6.1m

Gross profit

(504.0k)2.9m5.4m8.8m15.6m18.9m17.9m10.0m18.5m18.5m

Gross profit Margin, %

(23%)75%77%83%92%87%89%65%78%75%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

103.1m62.9m30.9m127.8m87.2m82.3m107.7m

Accounts Receivable

95.3k55.8m410.0k13.1m37.1m30.0m

Prepaid Expenses

3.4m5.5m5.4m5.1m

Inventories

502.3k760.9k3.8m1.8m7.6m16.5m15.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

35.8m12.0m14.4m27.0m28.3m73.5m58.9m119.0m66.8m42.9m197.2m159.2m147.3m174.6m117.8m87.9m45.7m87.8m112.0m183.1m128.6m98.7m

Accounts Receivable

403.2k199.6k46.4k56.0k101.0k2.4m5.1m8.8m15.1m22.6m29.3m30.4m21.5m27.9m30.4m

Prepaid Expenses

845.2k684.1k710.3k1.5m1.2m802.6k1.2m1.2m1.6m4.3m2.3m3.6m4.0m3.0m4.7m4.7m4.2m5.2m5.8m5.0m5.9m7.3m

Inventories

2.5m3.4m5.1m10.3m12.9m14.8m20.0m19.4m18.0m12.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.3m)(46.3m)(71.9m)(137.5m)(169.7m)(149.8m)(113.7m)

Depreciation and Amortization

120.3k238.2k1.2m2.0m1.7m1.7m

Inventories

(9.1m)46.9m(34.0m)(1.8m)(5.2m)(7.7m)(922.0k)

Accounts Payable

518.0k1.6m(992.7k)4.2m5.1m1.7m(6.6m)
USDQ1, 2014

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.1 x
Show all financial metrics

Flexion Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Flexion Therapeutics Online and Social Media Presence

Embed Graph

Flexion Therapeutics Company Culture

  • Overall Culture

    A+

    91/100

  • CEO Rating

    A+

    98/100

  • Compensation

    A+

    97/100

  • Diversity

    A+

    89/100

Learn more on Comparably

Flexion Therapeutics News and Updates

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference …

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference

BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fire…

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee

BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guide…

Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain

BURLINGTON, Mass., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a locally administered NaV1.7…

Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)

BURLINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the results from the randomized, open-label, Phase 2 pharmacokinetic (PK) trial of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Drugs in R&amp…

Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion’s audit committee.
Show more

Flexion Therapeutics Blogs

Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

ZILRETTA® ( triamcinolone acetonide extended-release injectable suspension) net sales were $28 .2 million in Q2 2021, reflecting growth of 15% over the previous quarter Net loss in Q2 2021 decreased by $10 .4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates Content Import Wed, 05/12/2021 - 16:01 Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates May 12, 2021 This release is a ba…

Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Content Import Wed, 04/28/2021 - 07:31 Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at th…

Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results

Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results Content Import Wed, 03/10/2021 - 16:01 Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results Mar 10, 2021 This release is a backfill from a News Wire …

Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020

Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020 Content Import Thu, 10/29/2020 - 16:31 Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020 Oct 29, 2020 This release is a backfill from …

Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference

Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference Content Import Wed, 09/09/2020 - 16:31 Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference Sep 09, 2020 This release is a backfill from a News…
Show more

Flexion Therapeutics Frequently Asked Questions

  • When was Flexion Therapeutics founded?

    Flexion Therapeutics was founded in 2007.

  • Who are Flexion Therapeutics key executives?

    Flexion Therapeutics's key executives are Scott A. Canute, Michael D. Clayman and Melissa Layman.

  • How many employees does Flexion Therapeutics have?

    Flexion Therapeutics has 272 employees.

  • What is Flexion Therapeutics revenue?

    Latest Flexion Therapeutics annual revenue is $85.6 m.

  • What is Flexion Therapeutics revenue per employee?

    Latest Flexion Therapeutics revenue per employee is $314.5 k.

  • Who are Flexion Therapeutics competitors?

    Competitors of Flexion Therapeutics include Alembic Pharmaceuticals, EMS Pharma and PPD.

  • Where is Flexion Therapeutics headquarters?

    Flexion Therapeutics headquarters is located at 10 Burlington Mall Road #301, Burlington.

  • Where are Flexion Therapeutics offices?

    Flexion Therapeutics has an office in Burlington.

  • How many offices does Flexion Therapeutics have?

    Flexion Therapeutics has 1 office.